TICKERNERD
Menu
ATRATRHealthcare · Medical Instruments & Supplies

ATR Stock Forecast: AptarGroup, Inc. Price Predictions for 2026-2027

Last close, 18 Aug 2026
$132
−0.01% on the day

The 8 Wall Street analysts covering AptarGroup, Inc. hold a median 12-month price target of $164 — +24.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 17 Aug 2026 — in the lower half.

Market cap
$8.4B
Ticker Nerd rank
47 / 100
Median analyst target
$164
Analysts covering
8
Total return, dividends reinvested
1W
−2.2%
1M
−0.3%
YTD
+9.2%
1Y
−3.0%
From 52W high
−8.9%
From 52W low
+18.1%
$112
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AptarGroup, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
92
Quality
90
Revisions
78
Issuance
52
Accruals
42
Growth
41
Momentum
26
Value
24
Size
17

Volatility (92): The share price has been relatively steady.

Value (24): The shares cost a lot relative to the profits and assets behind them.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200$220Oct 25Jan 26Apr 26Jul 26ATRHigh $220Median $164Low $155

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $155Median $164High $220

The green dot is the last close — the median target sits +24.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026Wells FargoMaintainsOverweight$145 → $155
4 May 2026Wells FargoMaintainsOverweight—
4 May 2026Wells FargoMaintainsOverweight$144 → $145
20 Mar 2026Wells FargoUpgradeOverweight—
6 Jan 2026Wells FargoDowngradeEqual-Weight—
3 Nov 2025BairdMaintainsOutperform—
3 Nov 2025Wells FargoMaintainsOverweight—
10 Sept 2025Wells FargoMaintainsOverweight—
4 Sept 2025KeybancInitiatesOverweight—
4 Aug 2025Raymond JamesMaintainsOutperform—
4 Aug 2025Wells FargoMaintainsOverweight—
18 July 2025Wells FargoMaintainsOverweight—
15 July 2025Raymond JamesMaintainsOutperform—
6 May 2025Wells FargoMaintainsOverweight—
22 Apr 2025Raymond JamesMaintainsOutperform—
10 Feb 2025BairdMaintainsOutperform—
10 Feb 2025Raymond JamesReiteratesOutperform—
10 Feb 2025Wells FargoMaintainsOverweight—
7 Jan 2025Raymond JamesInitiatesOutperform—
6 Jan 2025Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.1%
Analysts raising
0
Analysts cutting
3
Fundamentals

AptarGroup, Inc. (ATR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.8×

Cheaper than 34% of US stocks

Price / sales
2.1×

Cheaper than 52% of US stocks

Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
12.1×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
6.3%

Higher than 43% of US stocks

Earnings growth (YoY)
−21.6%

Higher than 19% of US stocks

Gross margin
35.8%

Higher than 44% of US stocks

Operating margin
12.5%

Higher than 68% of US stocks

Net margin
9.2%

Higher than 68% of US stocks

Returns & dividend
Return on equity
13.5%

Higher than 71% of US stocks

Return on assets
6.1%

Higher than 82% of US stocks

Dividend yield
1.5%

Higher than 35% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ATRAptarGroup, Inc.$8.4B
47
AVTRAvantor, Inc.$9.2B
79
RGENRepligen Corp.$9.5B
90
ALGNAlign Technology, Inc.$12.3B
82
BLCOBausch + Lomb Corp.$6.1B
85
TFXTeleflex, Inc.$5.9B
82
STVNStevanato Group SpA$5.8B
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AptarGroup, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATR news & analysis

Dividend Champion, Contender, And Challenger Highlights: Week August 16

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, covering companies that changed their dividends and those with upcoming ex-dividend dates for the week of August 16.

Why it matters — ATR watchers may monitor this weekly roundup for any changes to AptarGroup's dividend status or upcoming ex-dividend dates relevant to their holdings.

AptarGroup Q2 Earnings Beat Estimates on Pharma & Beverage Growth

Zacks Investment Research · 5 Aug 2026positive

AptarGroup reported Q2 earnings and revenue that beat estimates, driven by growth in its pharma and beverage segments, which helped push quarterly revenues above $1 billion for the first time despite margin pressure.

Why it matters — ATR watchers would note the milestone of surpassing $1 billion in quarterly revenue, showing strong demand in key end markets even as margins face headwinds.

Why AptarGroup (ATR) International Revenue Trends Deserve Your Attention

Zacks Investment Research · 3 Aug 2026neutral

A Zacks Investment Research report examines AptarGroup's international revenue performance and how it influences Wall Street analysts' expectations and the company's future prospects.

Why it matters — For ATR watchers, international revenue trends are a key driver of analyst projections and the company's growth outlook.

AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

AptarGroup published the transcript of its Q2 2026 earnings call on Seeking Alpha.

Why it matters — Earnings call transcripts provide investors with detailed management commentary on quarterly financial results and business outlook.

AptarGroup Q2 Earnings Call Highlights

MarketBeat · 31 July 2026positive

AptarGroup reported second-quarter sales growth across all three segments and adjusted earnings per share above its guidance range, driven by stronger-than-expected Pharma performance. The company also announced that CEO Stephan Tanda will retire later this year, with Gael Touya set to assume the role on Sept. 1.

Why it matters — ATR watchers would note the above-guidance earnings and upcoming CEO transition, both of which bear on the company's near-term performance and leadership direction.

FAQ

Frequently asked questions about ATR stock

What is the ATR stock price forecast for 2026-2027?

The 8 Wall Street analysts covering AptarGroup, Inc. have a median 12-month price target of $164, with estimates ranging from $155 to $220. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATR stock a buy right now?

Of the 8 analysts covering AptarGroup, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AptarGroup, Inc. 47 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATR?

As at 17 Aug 2026, AptarGroup, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).

Will ATR stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +24.5% from the last close, and Ticker Nerd's factor model ranks AptarGroup, Inc. 47 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATR stock forecast for 2030?

No analyst covering AptarGroup, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $155 to $220 over the next 12 months.

How has ATR stock performed over the past year?

AptarGroup, Inc. returned -3.0% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AptarGroup, Inc. do?

AptarGroup, Inc. is a global leader in designing and manufacturing drug delivery, consumer product dispensing, and active material science solutions for pharmaceutical, beauty, personal care, home care, food and beverage, and fragrance markets.

What is the latest news on ATR?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Dividend Champion, Contender, And Challenger Highlights: Week August 16". Seeking Alpha published a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, covering companies that changed their dividends and those with upcoming ex-dividend dates for the week of August 16.

Company

About AptarGroup, Inc.

AptarGroup, Inc. is a global leader in designing and manufacturing drug delivery, consumer product dispensing, and active material science solutions for pharmaceutical, beauty, personal care, home care, food and beverage, and fragrance markets. The company operates through three primary segments: Pharma, which focuses on specialized packaging and delivery systems including injectables for biologics, GLP-1 therapies, and central nervous system treatments; Beauty and Home, providing dispensing systems like pumps, aerosol valves, and closures; and Food and Beverage, offering sealing and active packaging solutions. AptarGroup serves diverse end markets with innovative technologies for dosing, dispensing, and protection, supporting prescription drugs, consumer health care, color cosmetics, and facial skincare. Its products emphasize precision, reliability, and sustainability, catering to global needs in healthcare and consumer goods. Founded in 1940 and headquartered in Crystal Lake, Illinois, AptarGroup maintains manufacturing facilities across North America, Europe, Asia, and South America.

CEO Mr. Stephan B. Tanda · 14,000 employees · United States · https://www.aptar.com